FDA notifications.  FDA approves half-strength Kaletra.
D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir